Compare TXG & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXG | KYMR |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.0B |
| IPO Year | 2019 | 2020 |
| Metric | TXG | KYMR |
|---|---|---|
| Price | $81.69 | $122.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 24 |
| Target Price | $77.50 | ★ $139.83 |
| AVG Volume (30 Days) | ★ 3.7M | 762.4K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,893,000.00 | $39,211,000.00 |
| Revenue This Year | N/A | $167.19 |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.06 | N/A |
| 52 Week Low | $12.44 | $55.66 |
| 52 Week High | $102.81 | $130.05 |
| Indicator | TXG | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 64.47 |
| Support Level | $74.60 | $110.64 |
| Resistance Level | $102.81 | $128.95 |
| Average True Range (ATR) | 6.01 | 5.16 |
| MACD | 0.47 | 1.72 |
| Stochastic Oscillator | 70.45 | 76.12 |
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.